OncoMatch/Clinical Trials/NCT06824883
Sintilimab, Pegaspargase Plus GemOx for Untreated Extranodal NK/T-Cell Lymphoma
Is NCT06824883 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Immunochemotherapy for extranodal nk/t-cell lymphoma.
Treatment: Immunochemotherapy — This is a single-arm phase 2 study designed to evaluate the safety and efficacy of sintilimab, pegaspargase combined with gemcitabine and oxaliplatin (P-P-GEMOX regimen) as first-line treatment for patients with ENKTL. The primary endpoint is the complete response rate (CRR) in the intention-to-treat population.The secondary endpoints were overall response rate (ORR), progression-free survival (PFS), overall survival (OS), and adverse events.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Hodgkin Lymphoma
Performance status
ECOG 0–3(Limited self-care)
Prior therapy
Lab requirements
Blood counts
ANC ≥ 1.5 × 10⁹/L (≥ 1.0 × 10⁹/L with bone marrow involvement); PLT ≥ 80 × 10⁹/L (≥ 50 × 10⁹/L with bone marrow involvement); HGB ≥ 80 g/L
Kidney function
Serum creatinine < 1.5 × ULN
Liver function
ALT < 3 × ULN; TBil < 1.5 × ULN
Cardiac function
NYHA heart function class 0-2; LVEF > 50%
Adequate bone marrow function: Absolute neutrophil count (ANC) ≥ 1.5 × 10⁹/L (≥ 1.0 × 10⁹/L in cases with bone marrow involvement); Platelet count (PLT) ≥ 80 × 10⁹/L (≥ 50 × 10⁹/L in cases with bone marrow involvement); Hemoglobin (HGB) ≥ 80 g/L. Adequate organ function: Alanine aminotransferase (ALT) < 3 × the upper limit of normal (ULN); Total bilirubin (TBil) < 1.5 × ULN; Serum creatinine < 1.5 × ULN; NYHA heart function class 0-2; Left ventricular ejection fraction (LVEF) > 50%.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify